TY - JOUR
T1 - Hypogammaglobulinemia
T2 - A contributing factor to multiple sclerosis fatigue?
AU - Diem, L.
AU - Evangelopoulos, M. E.
AU - Karathanassis, D.
AU - Natsis, V.
AU - Kamber, N.
AU - Hammer, H.
AU - Friedli, C.
AU - Chan, A.
AU - Helbling, A.
AU - Penner, I. K.
AU - Salmen, A.
AU - Walther, S.
AU - Stegmayer, K.
AU - Hoepner, R.
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/12
Y1 - 2022/12
N2 - Objective: Fatigue is one of the most disabling and difficult to treat symptoms of autoimmune diseases and frequently presents in people with multiple sclerosis (PwMS). Hypogammaglobulinemia for immunoglobulin G (IgG) affects approximately 8–25% of PwMS. We performed a retrospective analysis to investigate the association of MS-fatigue and IgG hypogammaglobulinemia. Methods: PwMS, treated at Eginition University Hospital Athens or at the University Hospital Bern, were included (n = 134 patients (Bern n = 99; Athens n = 35)). Mann Whitney U-test (MWT), ANOVA test, Chi2 test and multivariable linear regression models were run. Results: 97/134 (72.4%) PwMS reported fatigue. In the multivariable linear regression analysis, IgG serum concentration (–1.6, 95%CI –2.7 - –0.5, p = 0.006), daytime sleepiness (0.8, 95%CI 0.2–1.4, p = 0.009), and a depressive mood (1.1, 95%CI 0.8–1.4, p < 0.001) were significantly associated with fatigue. The impact of IgG serum concentration (-2.9 95%CI -4.7 - -1.1, p = 0.002) remained significant also in the subcohort of PwMS without depressive symptoms or daytime sleepiness. Conclusions: We found an association between IgG hypogammaglobulinemia and fatigue in PwMS (Level of Evidence IV), which might be translated to other autoimmune diseases. It bears a potential therapeutic consequence considering IgG supplementation strategies, if our finding can be validated prospectively.
AB - Objective: Fatigue is one of the most disabling and difficult to treat symptoms of autoimmune diseases and frequently presents in people with multiple sclerosis (PwMS). Hypogammaglobulinemia for immunoglobulin G (IgG) affects approximately 8–25% of PwMS. We performed a retrospective analysis to investigate the association of MS-fatigue and IgG hypogammaglobulinemia. Methods: PwMS, treated at Eginition University Hospital Athens or at the University Hospital Bern, were included (n = 134 patients (Bern n = 99; Athens n = 35)). Mann Whitney U-test (MWT), ANOVA test, Chi2 test and multivariable linear regression models were run. Results: 97/134 (72.4%) PwMS reported fatigue. In the multivariable linear regression analysis, IgG serum concentration (–1.6, 95%CI –2.7 - –0.5, p = 0.006), daytime sleepiness (0.8, 95%CI 0.2–1.4, p = 0.009), and a depressive mood (1.1, 95%CI 0.8–1.4, p < 0.001) were significantly associated with fatigue. The impact of IgG serum concentration (-2.9 95%CI -4.7 - -1.1, p = 0.002) remained significant also in the subcohort of PwMS without depressive symptoms or daytime sleepiness. Conclusions: We found an association between IgG hypogammaglobulinemia and fatigue in PwMS (Level of Evidence IV), which might be translated to other autoimmune diseases. It bears a potential therapeutic consequence considering IgG supplementation strategies, if our finding can be validated prospectively.
KW - Fatigue
KW - Immunoglobulin
KW - Multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=85137289753&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2022.104148
DO - 10.1016/j.msard.2022.104148
M3 - Article
C2 - 36063730
AN - SCOPUS:85137289753
SN - 2211-0348
VL - 68
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
M1 - 104148
ER -